Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
May 29, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Reports Financial Results for First Quarter 2024
May 28, 2024 16:30 ET
|
Cellectis Inc.
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 • Conference...
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
May 27, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Monthly information on share capital and company voting rights
May 16, 2024 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 16, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Monthly information on share capital and company voting rights
May 06, 2024 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
May 06, 2024 02:00 ET
|
Cellectis Inc.
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
May 02, 2024 16:30 ET
|
Cellectis Inc.
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
April 29, 2024 16:46 ET
|
Cellectis Inc.
• Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting • Execution of strategic...
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
April 22, 2024 16:30 ET
|
Cellectis Inc.
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs at ASGCT 2024
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
April 08, 2024 16:30 ET
|
Cellectis Inc.
Cellectis announces that preliminary data exploring novel TALEN® editing process in HSPCs will be presented at ASGCT 2024